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A 72-year-old male exsmoker of 60-pack-years had under-gone a high anterior resection, followed by chemotherapy 
(Leucovorin+5-Fluorouracil, S-1, FOLFOX-4+Bevacizumab, 
FOLFIRI+Bevacizumab) for rectal cancer with liver and 
sacral bone metastases 6 years ago. Because a nodal shadow 
had appeared in the right lower lobe of the lung, despite the 
disappearance of the liver and sacral metastases, he was 
referred to our department for a treatment of the pulmonary 
nodule.
Computed tomography showed an irregular nodule in 
the right lower lobe, which was confirmed as active by posi-
tron emission tomography, although there were no active 
lesions on the liver or sacral bone (Fig. 1A). The pulmonary 
lesion was assumed to be primary lung cancer, and right 
lower lobectomy with lymphadenectomy was performed. 
The cut sections revealed a whitish solid nodule encircled 
by a gray-whitish component with a maximum diameter 
of 4.5 cm (Fig. 1B). The central component was pathologi-
cally diagnosed as small-cell lung cancer (SCLC), which 
was 30% of the entire tumor, and the surrounding area was 
adenocarcinoma (70%) with papillary, acinar and lepidic 
components (formerly nonmucinous bronchioloalveolar 
carcinoma, 10%; Fig. 2 A– C). Both the components showed 
immunoreactivity to thyroid transcriptional factor 1, whereas 
synaptophysin and CD56 were detected only in the SCLC 
component. The pathological stage was finally determined to 
be IB. Each of the components was separately examined for 
mutations of epidermal growth factor receptor (EGFR) and 
anaplastic lymphoma kinase (ALK) by the direct sequencing 
method. A deletion in exon 19 of EGFR was detected only in 
the lepidic component, whereas only the SCLC component 
harbored variant 1 of echinoderm microtubule-associated 
protein-like 4 (EML4)-ALK fusion (Fig, 3A, B) and those 
were confirmed by immunohistochemistry (Fig. 3C, D). 
Figure. 3E shows gene mapping of the mutations in each 
component.
DISCUSSION
Gene mutations in tyrosine kinases play crucial roles 
in the pathogenesis of adenocarcinoma. Tumors with the 
EGFR gene, the most well-known tyrosine kinase which 
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FIGURE 1. A, Computed tomography showing an irregular 
nodule in the right lower lobe of lung. B, Cut sections of the 
tumor are seen by the encircled part.
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FIGURE 2.  Microscopic findings. A, 
Microscopic findings of the tumor 
consisting of SCLC (arrow) sur-
rounded by adenocarcinoma with 
papillary, acinar and lepidic compo-
nents (asterisk). Highly magnified 
images of (B) the SCLC (asterisk), the 
adenocarcinoma (arrow), and (C) the 
lepidic components. SCLC, small-cell 
lung cancer.
FIGURE 3.  A direct sequence analysis revealing (A) a deletion in exon 19 of EGFR in the adenocarcinoma and (B) a variant 
1 mutation of EML4-ALK in the SCLC. Immunoreactivity of the lepidic component to the deletion in exon 19 of EGFR 
using an antibody that specifically detects deleted EGFR (E746-A750del) (6B6, Cell Signaling, Danvers, MA) (C) and of the 
SCLC to ALK using primary antibody against ALK (5A4, Nichirei, Tokyo, Japan) (D). A polymer method was used for the 
immunohistochemical analysis, specifically, an intercalating antibody-enhanced polymer method was used for the detection 
of ALK. E, Gene mapping of the driver mutations in each component. EGFR, epidermal growth factor receptor; EML4-ALK, 
echinoderm microtubule-associated protein-like 4; SCLC, small-cell lung cancer; ALK, anaplastic lymphoma kinase.
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harbors activating mutations in exon 19 and 21, can be suc-
cessfully treated by EGFR-tyrosine kinase inhibitors (TKIs) 
in comparison to cytotoxic reagents.1 The EML4-ALK fusion 
gene also possesses a transforming activity2 and has attracted 
much attention because it might be a potential therapeutic 
target of ALK inhibitors in the treatment of adenocarci-
noma.3 Although EGFR mutations have already been identi-
fied in SCLCs (4%),4 there are no reports on the EML4-ALK 
translocation in SCLCs. Intriguingly, ALK translocation was 
detected in the SCLC component in the present case, whereas 
the exon 19 EGFR mutation was shown only in the lepidic 
component.
Adenocarcinoma with sensitive EGFR mutations can 
transform into SCLC in the process of acquiring resistance 
to EGFR-TKIs.5 This mechanism does not apply to the cur-
rent case, because the patient had not received EGFR-TKIs. 
Although the complexity of the combined histology and 
driver mutations in the present case has not been elucidated, 
this phenomenon suggests that ALK rearrangements could be 
involved in the pathogenesis of SCLC, which could be suc-
cessfully treated with ALK inhibitors.
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